Third, whereas the RPE+BM thickness in the RP patients was approximately within normal limits across the TZ (
Fig. 6C), the RPE+BM thickness in patients with CHM was abnormally thin by region IV
C and was sometimes thin even in the more central regions I
C to III
C (
Fig. 3C). Patients with STGD usually have a thin RPE+BM in their most affected region (region V
S;
Fig. 5C; blue rectangles in
Table 6). It is important to emphasize that we think that we were measuring the RPE+BM thickness, not the RPE thickness by itself. The RPE+BM thickness that we measured in the control eyes (average 19 μm) was similar to that measured in a recent human histologic study.
23 Further, in regions of the retina of patients with severe RP and a missing RPE on fundus examination, a thin RPE+BM band remained. The thinning of the RPE+BM by the end of the TZs in CHM and STGD was close to that in patients with severe RP. In particular, the RPE+BM thickness of the CHM patients in regions IV
C and V
C (≈10 μm) was close to the residual RPE+BM thickness of 9 μm (minRPE+BM) that we found in a group of patients with severe RP with measurable damage to the RPE. Our observation of a region I
C with normal OS and ONL+ thickness, but thin RPE+BM thickness in some CHM patients lends support to the possibility proposed in recent papers
7 –10 that the RPE is the primary site of disease in CHM, followed by the photoreceptors. Nonetheless, thinning of the RPE+BM is seen at the end of the TZ in all patients with CHM, including those whose OS layer appears to be affected before the RPE. This suggests that therapies targeting the RPE may also be of use in CHM. Although a thin RPE+BM was found in most patients with STGD by region V
S, RPE+BM thickness was found to be relatively normal in STGD patients at less severe locations in the TZ with already thinned ONL+ and OS layer. It therefore appears that photoreceptor loss can occur before RPE loss in STGD, consistent with some findings in the literature,
3,13,14 but in contrast to others.
11,12